BB-1701

BB-1701 这药可太有故事了！本来 Eisai 大手一挥，不要这款 HER2 靶向抗体- 药物偶联物了，结果它跟打不死的 “小强” 似的，居然还活得好好的。就在 Eisai 悄咪咪做决定的几周后，它的液体活检合作伙伴爆料，百利生物打算单干，自己推进这个项目，这可真是让人意想不到。 曾经的 “甜蜜” 合作：20 亿美元的诱人承诺 2023 年的时候，Eisai 那叫一个大方，大手一挥就同意给百利生物高达 20 亿美元，就为了获得 BB-1701 的选择权。那时候，阿斯利康和癌症药物界的 “好搭档” 第一三共，早就靠着 Enhertu 证明了 HER2 靶向 ADC 的 “重磅炸弹” 潜力。不过 Eisai 眼光独特，看中了 BB-1701，觉得它可能是同类里的 “扛把子”，还特别提到它基于埃立布林的有效载荷 - 连接子技术，这可是它的“秘密武器”，说不定能让这款 ADC 在 HER2 领域闯出一片天。 液体活检公司Angle称，BB-1701的完整2期研究正在进行中，药物疗效结果未知。（Daniel Mayer/iStock/Getty Images Plus） 说好一起到白头，你却半路放了手 合作期间，也不是没有好消息，合作伙伴报告说在实体瘤里看到了效果，就连之前用过另一种抗 HER2 ADC 治疗的乳腺癌患者都有反应。可谁能想到，上个月 Eisai 突然透露（PDF 警告），说决定不买 BB-1701 这个 “潜力股” 了，还记录了和这决定相关的减值损失，这可真是 “翻脸比翻书还快”。 Angle 的 “神助攻” 与新打算 Eisai 这一走，可把 Angle 这家液体活检公司给影响到了，它之前还给 BB-1701 的 2 期试验提供循环肿瘤细胞分析呢。周五的时候，Angle 出来说话了，说试验表明他们的检测方法能测量 HER2 状态随时间的变化，这可比基于组织的评估厉害多了。BB-1701 的完整 2 期研究还在进行中，药物疗效结果还不知道咋样呢，Eisai 就提前 “下车” 了。不过 Angle 也带来好消息，说百利生物确认要自己推进这个 ADC 项目。现在 Angle 还想和百利生物合作，一起搞BB-1701 开发的下一阶段。Eisai 呢，虽然不参与 BB-1701 项目了，但还得继续当埃立布林有效载荷的许可方，和百利生物有点 “剪不断理还乱” 的关系。 百利生物的 “艰难求生路” 这一系列变动，让中国的百利生物在 BB-1701 项目上没了全球合作伙伴，一下子就陷入了 “单打独斗” 的局面。在自家本土市场，百利生物的日子也不好过，Duality Biologics、GeneQuantum Healthcare 和江苏恒瑞医药等一批本地公司都在和它竞争。 BioNTech 在 2023 年拿下了 DualityBio 候选药物中国境外的权利，强生去年花 20 亿美元收购 Ambrx 的时候，也搞到了一种 HER2 靶向 ADC，百利生物这压力可不小啊！ 参考资料：https://www.fiercebiotech.com/biotech/eisais-abandoned-enhertu-challenger-set-live-blissbio 识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！ 请注明：姓名+研究方向！ 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

+Plus, news about Autolus, MacroGenics and BlissBio: Akeso bispecific looks promising in cervical cancer: The China-based biotech said Friday that all patients in a Phase 3 cervical cancer trial responded to treatment with a bispecific antibody called cadonilimab. The addition of the PD-1xCTLA-4 bispecific on top of chemoradiotherapy in the COMPASSION-18 study generated complete and partial response rates of 84.8% and 15.2%, respectively. Median PFS was not reached, but the 12-month PFS rate was 74.9%. Cadonilimab is already approved in China for patients with recurrent or metastatic cervical cancer who have not responded to platinum-based chemotherapy. — Elizabeth Cairns Pulmatrix to divest assets ahead of merger: The biotech will seek buyers for three of its pipeline programs as well as its iSPERSE platform technology. Pulmatrix in November agreed to a reverse merger with Cullgen, which was expected to close this month but is now set to close in the first half of 2025. — Max Gelman BioNTech’s option for Autolus CAR-T fizzles out: The German biotech allowed its option to lapse for AUTO1/22, a CAR-T cell therapy in Phase 1 trials for childhood acute lymphoblastic leukemia. Back in February 2024 , BioNTech paid $50 million in cash and bought $200 million of Autolus’ shares in a deal that granted it access to AUTO1/22. The deal also covered AUTO6NG, a programmed T-cell therapy in early trials in neuroblastoma, and Aucatzyl, which has since been approved for an aggressive form of leukemia. BioNTech declined to exercise its time-limited option to AUTO1/22 because of a pipeline prioritization , and it lapsed Feb. 8. — Elizabeth Cairns MacroGenics shelves prostate cancer ADC: The company had to stop dosing prostate cancer patients in a Phase 2 trial of its antibody-drug conjugate, called vobramitamab duocarmazine, in July . On Thursday , it said it would shut down all development and seek a partner for the product, which targets the tumor antigen B7-H3 and delivers a cytotoxic duocarmycin payload. MacroGenics said the results of the trial do not justify any more investment; in the patients treated before dosing was halted, mature median radiographic progression-free survival was 9.5 months with the lower dose and 10 months with the higher. — Elizabeth Cairns BlissBio to proceed with ADC on its own: Eisai had signed an option deal in 2023 to advance a BlissBio program called BB-1701, but last month said in its third-quarter earnings that it would no longer do so. Instead, BlissBio will develop BB-1701 on its own. Eisai had been partnered with liquid biopsy company Angle on development plans, and now Angle is planning to work with BlissBio. — Max Gelman